Aclaris Therapeutics Statistics
Total Valuation
ACRS has a market cap or net worth of $283.86 million. The enterprise value is $118.90 million.
Important Dates
The next estimated earnings date is Thursday, February 26, 2026, before market open.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRS has 108.35 million shares outstanding. The number of shares has increased by 62.68% in one year.
| Current Share Class | 108.35M |
| Shares Outstanding | 108.35M |
| Shares Change (YoY) | +62.68% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 2.83% |
| Owned by Institutions (%) | 57.89% |
| Float | 82.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.27 |
| Forward PS | 31.31 |
| PB Ratio | 2.36 |
| P/TBV Ratio | 2.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.92, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.92 |
| Quick Ratio | 3.92 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -113.23% and return on invested capital (ROIC) is -32.23%.
| Return on Equity (ROE) | -113.23% |
| Return on Assets (ROA) | -22.98% |
| Return on Invested Capital (ROIC) | -32.23% |
| Return on Capital Employed (ROCE) | -43.90% |
| Revenue Per Employee | $245,969 |
| Profits Per Employee | -$2.21M |
| Employee Count | 64 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.38% in the last 52 weeks. The beta is 0.43, so ACRS's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | +4.38% |
| 50-Day Moving Average | 2.77 |
| 200-Day Moving Average | 1.93 |
| Relative Strength Index (RSI) | 41.06 |
| Average Volume (20 Days) | 900,967 |
Short Selling Information
The latest short interest is 4.35 million, so 4.01% of the outstanding shares have been sold short.
| Short Interest | 4.35M |
| Short Previous Month | 3.78M |
| Short % of Shares Out | 4.01% |
| Short % of Float | 5.29% |
| Short Ratio (days to cover) | 3.64 |
Income Statement
In the last 12 months, ACRS had revenue of $15.74 million and -$141.68 million in losses. Loss per share was -$1.22.
| Revenue | 15.74M |
| Gross Profit | -43.40M |
| Operating Income | -65.81M |
| Pretax Income | -141.68M |
| Net Income | -141.68M |
| EBITDA | -65.74M |
| EBIT | -65.81M |
| Loss Per Share | -$1.22 |
Full Income StatementBalance Sheet
The company has $95.91 million in cash and $2.24 million in debt, with a net cash position of $164.97 million or $1.52 per share.
| Cash & Cash Equivalents | 95.91M |
| Total Debt | 2.24M |
| Net Cash | 164.97M |
| Net Cash Per Share | $1.52 |
| Equity (Book Value) | 120.10M |
| Book Value Per Share | 1.11 |
| Working Capital | 74.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$42.92 million and capital expenditures -$87,000, giving a free cash flow of -$43.01 million.
| Operating Cash Flow | -42.92M |
| Capital Expenditures | -87,000 |
| Free Cash Flow | -43.01M |
| FCF Per Share | -$0.40 |
Full Cash Flow StatementMargins
| Gross Margin | -275.68% |
| Operating Margin | -418.06% |
| Pretax Margin | -900.01% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -62.68% |
| Shareholder Yield | -62.68% |
| Earnings Yield | -49.91% |
| FCF Yield | -15.15% |
Analyst Forecast
The average price target for ACRS is $9.75, which is 272.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.75 |
| Price Target Difference | 272.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 29.55% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ACRS has an Altman Z-Score of -6.04 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.04 |
| Piotroski F-Score | 1 |
